• FAST Nanoparticles for Food-Grade Nutraceutical Delivery

  2026-09-10

  The 2026 reference study evaluates Facilitated Self-Assembling Technology (FAST) as a surfactant-free, food-grade route for producing stable nanoparticles from poorly soluble nutraceuticals. Its results support FAST as a promising formulation platform, while also indicating that product-specific bioavailability, composition, and regulatory studies remain necessary before broad translation.

• MLN4924: From Neddylation to Combination Strategy

  2026-09-10

  MLN4924 is more than a potent NEDD8-activating enzyme inhibitor: it is a mechanistic probe for connecting neddylation pathway inhibition with protein turnover, cell-cycle stress, and rational combination therapy. Evidence from head and neck squamous cell carcinoma research illustrates how pathway-level pharmacology can guide translational study design.

• Clasto-Lactacystin β-lactone Proteasome Workflows

  2026-09-09

  Use Clasto-Lactacystin β-lactone as a causal probe of proteasome-dependent protein turnover, not merely as a general toxicity reagent. This workflow connects RIPK3 stabilization, viral immune evasion, and quantitative proteasome assays while emphasizing controls, timing, and compound stability.

• Sunitinib Workflows for RTK and RCC Research

  2026-09-09

  Build reproducible Sunitinib assays for VEGFR-driven angiogenesis, renal cell carcinoma growth, apoptosis, and resistance studies. A practical workflow also shows how ferroptosis-focused combination experiments can reveal why some RCC models become more sensitive to RTK inhibition.

• Lactate Workflows for Metabolic–Immune Research

  2026-09-08

  Build reproducible L-lactate experiments that separate glycolytic output from lactate-driven signaling in cells, tissues, and tumor–immune models. This workflow combines compartment-aware sampling, controlled dosing, and mechanistic validation around the NAT1–ENO1–lactate–PD-L1 axis.

• OSMI-1: O-GlcNAc Transferase Inhibitor Guide

  2026-09-08

  OSMI-1 is a cell-permeable O-GlcNAc transferase inhibitor with a reported biochemical IC50 of 2.7 μM. It reduces protein O-GlcNAcylation and provides a defined perturbation for O-GlcNAcylation research, but its cytotoxicity and limited validation in disease models require controlled, cell-specific experiments.

• Spiroplasma Entry into Drosophila S2 Cells

  2026-09-07

  Wei and colleagues established a Drosophila Schneider 2 cell model to show that Spiroplasma eriocheiris actively invades insect cells, proliferates intracellularly, and induces substantial cellular stress. Pharmacological and cytoskeletal perturbation experiments implicate clathrin-mediated endocytosis and macropinocytosis, while providing no support for a caveola-dependent entry route.

• Tigecycline: Assay Strategy for CREC Research

  2026-09-07

  Tigecycline is a glycylcycline antibiotic with value beyond routine susceptibility testing. This article translates recent CREC plasmid-transmission findings into a practical, two-layer strategy for connecting resistance genotypes, bacterial phenotypes, and experimental assay design.

• (R)-MG132 for Causal Proteasome Assay Design

  2026-09-05

  (R)-MG132 is an inactive MG-132 enantiomer that strengthens proteasome inhibition validation by separating stereochemistry-dependent activity from nonspecific cellular effects. This article presents a causal assay framework connecting negative-control design with emerging HNRNPU lactylation and serine-metabolism research.

• Small-Molecule Antagonists of Shh–Heparin Binding

  2026-09-04

  Lamson and colleagues identified small molecules that disrupt Sonic hedgehog N-terminal fragment binding to heparin and inhibit ligand-driven Hedgehog signaling. The work establishes the Shh–heparin interface as a tractable extracellular target and uses Smoothened agonist rescue controls to distinguish ligand-level inhibition from downstream pathway blockade.

• JNJ-26854165 Workflow for p53 Drug Response Studies

  2026-09-04

  Build more informative Serdemetan experiments by separating growth arrest from true cell killing. This workflow connects HDM2-p53 biology with dose-response, apoptosis, migration, and radiation-combination assays while addressing solubility and endpoint-selection risks.

• AAL-993: Designing Causal Angiogenesis Assays

  2026-09-03

  AAL-993 is a selective VEGF receptor inhibitor for connecting receptor-level pharmacology with tumor angiogenesis research. This guide presents a causal assay framework that distinguishes VEGFR signaling, downstream pathway phenotypes, and translational limitations.

• a-MSH, amide Workflows for Pigmentation Research

  2026-09-03

  Use a-MSH, amide as a controlled melanogenic stimulus to build reproducible pigmentation assays, validate melanocortin receptor responses, and separate pathway activation from compound toxicity. The workflow also shows how to extend a B16F10 melanogenesis model into carefully bounded inflammation studies without confusing an inducer with an anti-melanogenic treatment.

• Early Life Adversity, Oxytocin, and Innate Fear

  2026-09-02

  This Communications Biology Article in Press identifies an oxytocin-dependent superior colliculus pathway through which early life adversity weakens looming-evoked innate defensive behavior in mice. By combining a social-deprivation model, behavioral testing, receptor analysis, circuit manipulation, and intranasal oxytocin rescue, the study connects early experience with altered visual threat processing and suggests a framework for evaluating restorative interventions.

• CD28–ARS2 Control of CD8+ T Cell Metabolism

  2026-09-02

  The reference study identifies a CD28–ARS2 signaling axis that remodels alternative splicing of PKM, favoring PKM2 and enabling metabolic flexibility in activated CD8+ T cells. Its findings connect costimulatory signaling to glucose utilization, IFNγ production, and antitumor effector function through a mechanism that operates independently of CD28-driven PI3K activation.

8554 records 2/571 page Previous Next 12345 下5页 Last page